NCT06315595

Brief Summary

This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
54mo left

Started Sep 2015

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Sep 2015Sep 2030

Study Start

First participant enrolled

September 30, 2015

Completed
8.5 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 18, 2024

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2030

Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

15 years

First QC Date

March 12, 2024

Last Update Submit

April 14, 2026

Conditions

Prostate Neoplasm

Outcome Measures

Primary Outcomes (1)

  • Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion

    Assessed by comparison of two images made from the raw data set but reconstructed using the standard vs. an alternative algorithm (to be determined during study). Data will be tabulated and analyzed statistically.

    Baseline (at enrollment); possible second scan at a later date

Study Arms (1)

Observational

Participants undergo a non-contrast MRI on study and may optionally undergo a second non-contrast MRI on study. Participants may also undergo blood sample collection on study.

Other: Non-Interventional Study

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult male volunteers as well as Mayo patients for whom a prostate MRI exam has been clinically indicated and ordered. In some cases such as for evaluation of the vasculature of the pelvis it may be useful to extend the inclusion criteria of volunteers to adult females.

You may qualify if:

  • Adults

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

ACTIVE NOT RECRUITING

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Stephen J. Riederer, PhD

    Mayo Clinic in Rochester

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015mayocliniccancerstudies@mayo.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2024

First Posted

March 18, 2024

Study Start

September 30, 2015

Primary Completion (Estimated)

September 30, 2030

Study Completion (Estimated)

September 30, 2030

Last Updated

April 17, 2026

Record last verified: 2026-04

Locations

US(2)